Witzens-Harig M - Search Results

1

Cellular Immunotherapy in B-Cell Malignancy.

Schwarzbich MA, Witzens-Harig M. Schwarzbich MA, et al. Oncol Res Treat. 2017;40(11):674-681. doi: 10.1159/000481946. Epub 2017 Oct 20. Oncol Res Treat. 2017. PMID: 29065420 Review.

2

Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.

Lehners N, Krämer I, Schwarzbich MA, Ho AD, Witzens-Harig M. Lehners N, et al. Leuk Lymphoma. 2016 Nov;57(11):2619-25. doi: 10.3109/10428194.2016.1157869. Epub 2016 Mar 21. Leuk Lymphoma. 2016. PMID: 26999040

3

Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.

Kriegsmann K, Rieger M, Schwarzbich MA, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD, Witzens-Harig M, Wuchter P. Kriegsmann K, et al. Eur J Haematol. 2018 Jul;101(1):12-20. doi: 10.1111/ejh.13064. Epub 2018 May 17. Eur J Haematol. 2018. PMID: 29575332

4

Ibrutinib.

Charalambous A, Schwarzbich MA, Witzens-Harig M. Charalambous A, et al. Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7. Recent Results Cancer Res. 2018. PMID: 30069629

5

Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.

Lisenko K, Cremer M, Schwarzbich MA, Kriegsmann M, Ho AD, Witzens-Harig M, Wuchter P. Lisenko K, et al. Biol Blood Marrow Transplant. 2016 Aug;22(8):1397-1402. doi: 10.1016/j.bbmt.2016.03.030. Epub 2016 Apr 7. Biol Blood Marrow Transplant. 2016. PMID: 27060439 Free article.

6

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.

Cremer M, Schwarzbich MA, Schöning T, Lisenko K, Ho AD, Witzens-Harig M. Cremer M, et al. Ann Hematol. 2017 Sep;96(9):1573-1575. doi: 10.1007/s00277-017-3044-4. Epub 2017 Jun 16. Ann Hematol. 2017. PMID: 28623395 No abstract available.

7

NKT cells - New players in CAR cell immunotherapy?

Kriegsmann K, Kriegsmann M, von Bergwelt-Baildon M, Cremer M, Witzens-Harig M. Kriegsmann K, et al. Eur J Haematol. 2018 Dec;101(6):750-757. doi: 10.1111/ejh.13170. Epub 2018 Oct 9. Eur J Haematol. 2018. PMID: 30187578 Review.

8

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Witzens-Harig M, et al. Br J Haematol. 2015 Dec;171(5):710-9. doi: 10.1111/bjh.13652. Epub 2015 Oct 9. Br J Haematol. 2015. PMID: 26449739 Free article. Clinical Trial.

9

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J. Angelova AL, et al. Front Oncol. 2017 May 12;7:93. doi: 10.3389/fonc.2017.00093. eCollection 2017. Front Oncol. 2017. PMID: 28553616 Free PMC article.

10

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.

Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M. Brandt J, et al. Leuk Lymphoma. 2010 Nov;51(11):2012-20. doi: 10.3109/10428194.2010.513749. Epub 2010 Sep 21. Leuk Lymphoma. 2010. PMID: 20858092

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters